RSV vaccine safety and immune response in high-risk adults
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a new RSV vaccine designed to protect adults with chronic health conditions from severe RSV disease (a respiratory infection). Researchers will monitor how safe the vaccine is and how well your immune system responds to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have at least one chronic health condition affecting your lungs, heart, kidneys, liver, nervous system, blood, or metabolism
- You have never received an RSV vaccine before
- You are willing to receive the study vaccine and attend follow-up visits
- You are able to provide informed consent and participate in study procedures
- Your current health condition and medications are reviewed and deemed safe by the study doctor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This study tests how your body's immune system responds to a new respiratory syncytial virus (RSV) vaccine. RSV is a common virus that causes respiratory infections, especially in older adults. The vaccine may help protect you from RSV disease.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This trial tests a new vaccine (MKK900) to see if it is safe and works well in healthy adult women. It is designed to protect against RSV, a common virus that can be serious in newborns and older adults. The vaccine is being developed for use during pregnancy to pass protection to babies.
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.